CXCR7 as a chemokine receptor for SDF-1 promotes gastric cancer progression via MAPK pathways

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther. 2014;40:250–260.
   PubMed Web of Science ®Google Scholar
• Lee SY, Oh SC. Changing strategies for target therapy in gastric cancer. World J Gastroenterol. 2016;22:1179–1189.
   PubMed Web of Science ®Google Scholar
• Xu W, Yang Z, Lu N. Molecular targeted therapy for the treatment of gastric cancer. J Exp Clin Cancer Res. 2016;35:1
   PubMed Web of Science ®Google Scholar
• Roy I, Evans DB, Dwinell MB. Chemokines and chemokine receptors: update on utility and challenges for the clinician. Surgery. 2014;155:961–973.
   PubMed Web of Science ®Google Scholar
• Balkwill FR. The chemokine system and cancer. J Pathol. 2012;226:148–157.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Savino B, Locati M, et al. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010;21:27–39.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16:2927–2931.
   PubMed Web of Science ®Google Scholar
• Cojoc M, Peitzsch C, Trautmann F, et al. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Onco Targets Ther. 2013;6:1347–1361.
   PubMedGoogle Scholar
• Sanchez-Martin L, Sanchez-Mateos P, Cabanas C. CXCR7 impact on CXCL12 biology and disease. Trends Mol Med. 2013;19:12–22.
   PubMed Web of Science ®Google Scholar
• Liu Z, Teng XY, Meng XP, et al. Expression of stromal cell-derived factor 1 and CXCR7 ligand receptor system in pancreatic adenocarcinoma. World J Surg Oncol. 2014;12:348.
   PubMed Web of Science ®Google Scholar
• Wang HX, Tao LY, Qi KE, et al. Role of CXC chemokine receptor type 7 in carcinogenesis and lymph node metastasis of colon cancer. Mol Clin Oncol. 2015;3:1229–1232.
   PubMedGoogle Scholar
• Iwakiri S, Mino N, Takahashi T, et al. Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer. Cancer. 2009;115:2580–2593.
   PubMed Web of Science ®Google Scholar
• Kurban S, Tursun M, Kurban G, et al. Role of CXCR7 and effects on CXCL12 in SiHa cells and upregulation in cervical squamous cell carcinomas in Uighur women. Asian Pac J Cancer Prev. 2014;15:9211–9216.
   PubMedGoogle Scholar
• Hattermann K, Held-Feindt J, Lucius R, et al. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res. 2010;70:3299–3308.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Jo DY. The role of the CXCR4/CXCL12 axis and its clinical implications in gastric cancer. Histol Histopathol. 2012;27:1155–1161.
   PubMed Web of Science ®Google Scholar
• Shi A, Dong L, Shi H, et al. [Expression of chemokine receptor CXCR7 in gastric cancer tissues and cell lines]. Nan Fang Yi Ke Da Xue Xue Bao. 2014;34:1780–1784.
   PubMedGoogle Scholar
• Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat. 1995;36:169–180.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408.
   PubMed Web of Science ®Google Scholar
• Singh AK, Arya RK, Trivedi AK, et al. Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12. Cytokine Growth Factor Rev. 2013;24:41–49.
   PubMed Web of Science ®Google Scholar
• Li XX, Zheng HT, Huang LY, et al. Silencing of CXCR7 gene represses growth and invasion and induces apoptosis in colorectal cancer through ERK and beta-arrestin pathways. Int J Oncol. 2014;45:1649–1657.
   PubMed Web of Science ®Google Scholar
• Schrevel M, Karim R, ter Haar NT, et al. CXCR7 expression is associated with disease-free and disease-specific survival in cervical cancer patients. Br J Cancer. 2012;106:1520–1525.
   PubMed Web of Science ®Google Scholar
• Liu Z, Sun DX, Teng XY, et al. Expression of stromal cell-derived factor 1 and CXCR7 in papillary thyroid carcinoma. Endocr Pathol. 2012;23:247–253.
   PubMed Web of Science ®Google Scholar
• Tachezy M, Zander H, Gebauer F, et al. CXCR7 expression in esophageal cancer. J Transl Med. 2013;11:238
   PubMed Web of Science ®Google Scholar
• Luker KE, Gupta M, Luker GD. Imaging chemokine receptor dimerization with firefly luciferase complementation. FASEB J. 2009;23:823–834.
   PubMed Web of Science ®Google Scholar
• Neve Polimeno M, Ierano C, D'Alterio C, et al. CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not. Cell Mol Immunol. 2015;12:474–482.
   PubMed Web of Science ®Google Scholar
• Heinrich EL, Lee W, Lu J, et al. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells. J Transl Med. 2012;10:68
   PubMed Web of Science ®Google Scholar
• Melo RCC, Longhini AL, Bigarella CL, et al. CXCR7 is highly expressed in acute lymphoblastic leukemia and potentiates CXCR4 response to CXCL12. PLoS One. 2014;9:e85926
   PubMed Web of Science ®Google Scholar
• Ierano C, Santagata S, Napolitano M, et al. CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells. Cell Death Dis. 2014;5:e1310
   PubMed Web of Science ®Google Scholar
• Lin L, Han MM, Wang F, et al. CXCR7 stimulates MAPK signaling to regulate hepatocellular carcinoma progression. Cell Death Dis. 2014;5:e1488
   PubMed Web of Science ®Google Scholar
• Liu C, Pham K, Luo D, et al. Expression and functional heterogeneity of chemokine receptors CXCR4 and CXCR7 in primary patient-derived glioblastoma cells. PLoS One. 2013;8:e59750.
   Google Scholar
• Hu SC, Yu HS, Yen FL, et al. CXCR7 expression correlates with tumor depth in cutaneous squamous cell carcinoma skin lesions and promotes tumor cell survival through ERK activation. Exp Dermatol. 2014;23:902–908.
   PubMed Web of Science ®Google Scholar
• Low HB, Zhang Y. Regulatory Roles of MAPK Phosphatases in Cancer. Immune Netw. 2016;16:85–98.
   PubMedGoogle Scholar
• Levoye A, Balabanian K, Baleux F, et al. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood. 2009;113:6085–6093.
   PubMed Web of Science ®Google Scholar
• Coggins NL, Trakimas D, Chang SL, et al. CXCR7 controls competition for recruitment of β-arrestin 2 in cells expressing both CXCR4 and CXCR7. PLoS One. 2014;9:e98328.
   PubMed Web of Science ®Google Scholar
• Rajagopal S, Kim J, Ahn S, et al. Beta-arrestin- but not G protein-mediated signaling by the “decoy” receptor CXCR7” . Proc Natl Acad Sci U S A. 2010;107:628–632.
   PubMed Web of Science ®Google Scholar
• Decaillot FM, Kazmi MA, Lin Y, et al. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. J Biol Chem. 2011;286:32188–32197.
   PubMed Web of Science ®Google Scholar
• Birner P, Tchorbanov A, Natchev S, et al. The chemokine receptor CXCR7 influences prognosis in human glioma in an IDH1-dependent manner. J Clin Pathol. 2015;68:830–834.
   PubMed Web of Science ®Google Scholar
• Hao M, Zheng J, Hou K, et al. Role of chemokine receptor CXCR7 in bladder cancer progression. Biochem Pharmacol. 2012;84:204–214.
   PubMed Web of Science ®Google Scholar
• Zheng K, Li HY, Su XL, et al. Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2010;29:31.
   PubMed Web of Science ®Google Scholar
• Wang J, Shiozawa Y, Wang Y, et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem. 2008;283:4283–4294.
   PubMed Web of Science ®Google Scholar